Synopsis: Biocon Ltd reported a steady operational performance in Q4 FY26 driven by growth in its Biosimilars and CRDMO businesses. The company posted consolidated revenue growth on a year-on-year basis while maintaining strong momentum across key verticals. Along with the quarterly results, Biocon also announced a final dividend of Rs. 0.50 per share for FY26.
Biocon Ltd is one of India’s leading biopharmaceutical companies focused on biosimilars, generics, research services, and specialty biologics. The company operates across multiple segments including Generics, Biosimilars, and CRDMO (Contract Research, Development and Manufacturing Organization). Through its subsidiaries and global partnerships, Biocon has built a strong presence in regulated international markets including the US, Europe, and emerging economies.
Biocon Ltd currently has a market capitalization of approximately Rs. 63,183 crore, with the stock trading near Rs. 392 per share up by 2.70% compared to its previous close of Rs. 382.25. The stock touched an intraday level of around Rs. 392.8, gaining nearly 2.8% during the trading session following the announcement. The company has a book value of Rs. 200 per share and trades at a P/E ratio of 77. Biocon reported ROCE of 6.25% and ROE of 4.76%.
Biocon reported consolidated net sales/income from continuing operations of approximately Rs. 4,517 crore during Q4 FY26, compared to around Rs. 4,417 crore reported in Q4 FY25, registering moderate year-on-year growth. Total segment revenue during the quarter stood at approximately Rs. 4,639 crore.
The company’s Biosimilars segment continued to remain the biggest contributor, generating revenue of approximately Rs. 2,756 crore during the quarter, compared to around Rs. 2,463 crore reported in the same quarter last year. The CRDMO business also delivered stable growth, with quarterly revenue rising to approximately Rs. 1,037 crore.
On a sequential basis, Biocon reported improvement across major business segments during Q4 FY26. Net sales/income from continuing operations increased from approximately Rs. 4,173 crore in Q3 FY26 to around Rs. 4,517 crore in Q4 FY26. The Biosimilars segment revenue improved from approximately Rs. 2,497 crore to around Rs. 2,756 crore sequentially.
CRDMO revenue also increased from nearly Rs. 917 crore in the December quarter to approximately Rs. 1,037 crore in the March quarter. Profit before tax and exceptional items rose sharply from around Rs. 226 crore in Q3 FY26 to approximately Rs. 328 crore in Q4 FY26, indicating improved operational efficiency and better segment performance.
The Board of Directors of Biocon recommended a final dividend of Rs. 0.50 per equity share having a face value of Rs. 5 each for the financial year ended March 31, 2026.The dividend is subject to shareholder approval at the upcoming Annual General Meeting (AGM).
Biocon delivered a stable Q4 FY26 performance with sequential improvement across key business verticals, especially Biosimilars and CRDMO operations. The company continues to strengthen its global biologics footprint while expanding its research and manufacturing capabilities. The announcement of a Rs. 0.50 dividend further highlighted management’s confidence in the business outlook.
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
